• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Obstetrics

Adding bevacizumab may not improve breast cancer survival

byMonica ParksandDavid Wang
March 12, 2015
in Obstetrics, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In a phase III trial of over 370 patients with advanced breast cancer, the addition of anti-vascular endothelial growth factor (VEGF) agent bevacizumab to endocrine therapy (ET) for breast cancer did not significantly increase progression free or overall survival compared to ET alone. 

Evidence Rating Level: 1 (Excellent)

Study Rundown: In patients with hormone-receptor positive breast cancer, adjuvant endocrine therapy (ET) with an aromatase inhibitor such as letrozole has demonstrated improved overall survival. However, resistance to ET may develop over time which limits the treatment options for these patients. ET resistance is hypothesized to be mediated by neoangiogenesis, particularly the overexpression of vascular endothelial growth factor (VEGF) within breast cancer cells. Thus, the purpose of this trial was to evaluate the effect of the addition of bevacizumab, a VEGF-inhibitor to ET. The Phase III trial randomized over 370 hormone positive, HER2-negative breast cancer patients to ET alone or ET plus bevacizumab. After a median follow-up of 23 months, patients in the ET plus bevacizumab arm did not demonstrate significant improvement in progression free survival, time to treatment failure, or overall survival compared to ET alone. Significant adverse events, such as thromboembolic events and hypertension, were also higher in the ET plus bevacizumab group. The results of this trial oppose the addition of bevacizumab in patients with hormone receptor-positive/HER-2 negative advanced breast cancer. The strength of the trial is the randomized design and the a priori requirement of treatment success. This trial is applicable to the specific patient population of patients with hormone-receptor positive advanced breast cancer; additional trials are required to evaluate the effect of bevacizumab in patients with hormone receptor-positive metastatic breast cancer.

Click to read the study in JCO

Relevant Reading: Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma

In-Depth [randomized controlled trial]: The Letrozole/Fulvestrant and Avastin (LEA) study was a phase III, multicenter, open-labelled trial from Spain and Germany to analyze the effect of adding bevacizumab to ET in patients with hormone receptor-positive/HER2 negative breast cancer. Overall, 374 breast cancer patients were recruited from 2007 to 2011 and randomized to either ET (letrozole or fulvestrant) alone or ET with bevacizumab. Exclusion criteria included prior treatment for metastatic disease, prior treatment with anti-VEGF agents, and rapidly progressive disease or poor performance status. The primary end point was progression-free survival (PFS); secondary endpoints included overall survival (OS), time to treatment failure (TTF), overall response rate (ORR), clinical benefit rate (CBR), and response duration (RD). After a median follow-up time was 23.7 months. Median PFS was 19.3 months (95%CI 16.5-22.1) in the combined treatment arm and 14.4 months (95%CI 11.4-17.5) in the ET-only arm (p = 0.125). OS for the two arms was 52.1 and 51.8 months, respectively (HR 0.87; 95%CI 0.58-1.32; p = 0.518). There was a significantly increased incidence of grade 3 to 4 adverse events in the ET plus bevacizumab arm including hypertension, aminotransferatse elevation, and proteinuria. Eight patients (4.2%) in the combination arm died within 30 days of end of treatment. There were no toxicity-related deaths in the ET alone arm.

Image: PD

RELATED REPORTS

#VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation

#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer

Religious-based interventions improve illness perception in breast cancer patients

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: bevacizumabBreast Cancer
Previous Post

Omeprazole versus placebo for bleeding peptic ulcer [Classics Series]

Next Post

Decision aids maybe be underutilized in treating prostate cancer

RelatedReports

#VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation
StudyGraphics

#VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation

January 31, 2023
#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer
StudyGraphics

#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer

January 24, 2023
Palliative care consultation linked to lower deaths by failed code resuscitation
Oncology

Religious-based interventions improve illness perception in breast cancer patients

January 9, 2023
Early palliative care may improve survival in advanced cancer
Wellness

Wellness Check: Spirituality

January 5, 2023
Next Post
Long-term active surveillance may be safe in low-risk prostate cancer

Decision aids maybe be underutilized in treating prostate cancer

Stepped-care management useful for chronic pain treatment in veterans (ESCAPE Trial)

Stepped-care management useful for chronic pain treatment in veterans (ESCAPE Trial)

Appropriate use criteria for angiography may frequently miss obstructive coronary artery disease

Appropriate use criteria for angiography may frequently miss obstructive coronary artery disease

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Dual antiplatelet therapy discontinued 9 months after percutaneous coronary intervention associated with improved morbidity and mortality
  • Concordance of diagnosis of autism spectrum disorder made by pediatricians vs multidisciplinary specialist teams
  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options